Table 3. (A) Associations between clinical variables and androgen receptor phosphorylation sites. (B) Associations between clinical variables and candidate kinases.
Clinical variables
|
|||||||
---|---|---|---|---|---|---|---|
Proteins | Age (<70 vs ⩾70 years) | Gleason (<7 vs =7 vs >7) | Diagnosis PSA (<10 vs 10–20 vs >20 ng ml−1 | Recurrence PSA (<10 vs 10–20 vs >20 ng ml−1) | Lymphovascular invasion (presence vs absence) | Presence of metastases (presence vs absence) | Ki67 (⩽median vs >median) |
A | |||||||
AR
| |||||||
Cytoplasm | 0.909 | 0.841 | 0.979 | 0.496 | 0.028 | 0.061 | 0.230 |
Nucleus | 0.284 | 0.450 | 0.301 | 0.380 | 0.006 | 0.107 | 0.154 |
Total | 0.422 | 0.464 | 0.493 | 0.800 | 0.002 | 0.027 | 0.627 |
pAR
S81
| |||||||
Cytoplasm | 0.035 | 0.811 | 0.269 | 0.566 | 0.175 | 0.660 | 0.498 |
Nucleus | 0.651 | 0.401 | 0.462 | 0.601 | 0.666 | 0.229 | 0.039 |
Total | 0.220 | 0.425 | 0.389 | 0.632 | 0.290 | 0.195 | 0.041 |
pAR
S94
| |||||||
Cytoplasm | 0.447 | 0.714 | 0.437 | 0.820 | 0.234 | 0.165 | 0.040 |
Nucleus | 0.651 | 0.069 | 0.726 | 0.386 | 0.234 | 0.892 | 0.361 |
Total | 0.754 | 0.417 | 0.964 | 0.496 | 0.864 | 0.554 | 0.191 |
pAR
S308
| |||||||
Cytoplasm | 0.169 | 0.567 | 0.441 | 0.848 | 0.386 | 0.656 | 0.662 |
Nucleus | 0.854 | 0.324 | 0.049 | 0.413 | 0.836 | 0.601 | 0.284 |
Total | 0.515 | 0.651 | 0.109 | 0.375 | 0.769 | 0.906 | 0.531 |
pAR
S515
| |||||||
Cytoplasm | 0.221 | 0.109 | 0.181 | 0.273 | 0.018 | 0.040 | 0.233 |
Nucleus | 0.042 | 0.336 | 0.052 | 0.116 | 0.673 | 0.948 | 0.156 |
Total | 0.048 | 0.120 | 0.287 | 0.120 | 0.463 | 0.528 | 0.229 |
pAR
S650
| |||||||
Cytoplasm | 0.046 | 0.446 | 0.976 | 0.761 | 0.773 | 0.750 | 0.260 |
Nucleus | 0.018 | 0.531 | 0.169 | 0.935 | 0.279 | 0.216 | 0.756 |
Total | 0.020 | 0.465 | 0.216 | 0.827 | 0.516 | 0.447 | 0.504 |
B | |||||||
Cdk1
| |||||||
Cytoplasm | 0.320 | 0.259 | 0.741 | 0.129 | 0.232 | 0.690 | 0.436 |
Nucleus | 0.665 | 0.898 | 0.255 | 0.464 | 0.563 | 0.353 | 0.838 |
Total | 0.187 | 0.831 | 0.277 | 0.130 | 0.583 | 0.432 | 0.879 |
pCdk1
161
| |||||||
Cytoplasm | 0.165 | 0.929 | 0.091 | 0.298 | 0.640 | 0.192 | 0.494 |
Nucleus | 0.084 | 0.255 | 0.164 | 0.047 | 0.389 | 0.259 | 0.630 |
Total | 0.044 | 0.263 | 0.108 | 0.017 | 0.621 | 0.204 | 0.918 |
pERK1/2
| |||||||
Cytoplasm | 0.293 | 0.175 | 0.854 | 0.639 | 0.471 | 0.180 | 0.530 |
Nucleus | 0.908 | 0.329 | 0.990 | 0.152 | 0.147 | 0.674 | 0.033 |
Total | 0.315 | 0.555 | 0.936 | 0.569 | 0.160 | 0.428 | 0.280 |
Abbreviations: AR=androgen receptor; PSA=prostate-specific antigen.
Cytoplasmic, nuclear and total (cytoplasmic+nuclear) expression of androgen receptor and phosphorylated androgen receptor (A) and candidate kinases (Cdk1, pCdk1161 and pERK1/2) (B) were examined for significant relationships with clinical variables as shown. Protein expression scores were used and clinical variables were divided into groups. When the clinical variable consisted of two independent groups the Mann–Whitney U-test was performed, and >2 independent groups the Kruskal–Wallis test was used. Significant associations are highlighted in bold.